SGLT2 Inhibition in Hemodialysis
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 220 participants.
Also called NCT05179668
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 220 participants
- Sponsor
- Registry
-
NCT05179668 -
2021-000733-14
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Austria
- Registry status
- Completed
Technical summary
Registry record NCT05179668. Randomized; triple masking; primary purpose treatment. Start 2022-10-01 (actual); primary completion 2025-07-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- SGLT2 Inhibition in Hemodialysis
- Acronym
- DAPA-HD
- Condition
- Kidney Failure
- Condition
- Hemodialysis
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Chronic Kidney Disease
- Condition
- Left Ventricular Hypertrophy
- Intervention (Drug)
- Dapagliflozin 10 MG
- Intervention (Drug)
- Placebo
- Lead sponsor
- Medical University of Vienna
Record details
- Record id
cardio:ct-nct05179668- Content hash
c9e94ba0a4c75cd437056707d37a00e45fac30f450f2ad60378f222acb1aff86